SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Spironolactone W/ Hydrochlorothiazide patents expire, and when can generic versions of Spironolactone W/ Hydrochlorothiazide launch?
Spironolactone W/ Hydrochlorothiazide is a drug marketed by Ivax Pharms, Lederle, Parke Davis, Purepac Pharm, Upsher Smith, Usl Pharma, Vangard, and Watson Labs. and is included in nine NDAs.
The generic ingredient in SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE is hydrochlorothiazide; spironolactone. There are thirty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; spironolactone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE?
- What are the global sales for SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE?
Summary for SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Clinical Trials: | 9 |
Patent Applications: | 30 |
DailyMed Link: | SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE at DailyMed |
Recent Clinical Trials for SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Chiang Mai University | Phase 3 |
Medical University of Bialystok | N/A |
Shanghai Jiao Tong University School of Medicine | Phase 4 |
See all SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE clinical trials